7 / 7
Page 23
Volume 2
Journal of Molecular Cancer
Cancer & Primary Healthcare 2019
May 20-21, 2019
Cancer Research & Oncology
Primary Healthcare and Medicare Summit
May 20-21, 2019 | Rome, Italy
25
th
Global Meet on
World Congress on
&
New Immunomodulatory Targets and Next Generation Active Immune Checkpoint
Control Immunotherapy
Jian Ni
Nuance Biotech (Shenzhen) Co. Ltd. China
C
hallenges remain inexpanding the target space, developingnext-generationactive immune immunotherapy
with improved efficacy and safety. This presentation focuses the leading immunomodulatory pathways as
well as therapeutic targets we have identified in B7 superfamily members : B7-H1
（
PD-L1
）
B7-H2
,
B7-H3
and B7-H4
,
TNF ligands and receptor superfamily : Blys
,
DR3
,
DR4
,
DR5
,
DR6
,
GITR
,
GITRL
,
TR2
,
LIGHT
,
TR6
,
TL1, RANK
,
TNFRSF19
,
RELT
,
TR1
,
DcR1 and DcR2
,
Siglecs family: Siglec 5
,
7
,
8
,
9
,
10
,
11 and Galectin
family: Galectin 9
,
10
,
11
,
12. The abnormal expression of galectins is known to be linked to the development,
progression and metastasis of cancers. tumor-derived galectins can have bifunctional effects on tumor and
immune cells. This talk focuses on the biological effects of galectin-1, galectin-3 and galectin-9 in various
cancers and discusses anticancer therapies that target these molecules. Siglecs comprise a family of 15 members
of sialic acid-binding receptors. Many Siglecs function as inhibitory receptors on innate and adaptive immune
cells and may contribute to the attenuation of immune responses to tumors. Siglecs are mostly inhibitory
receptors similar to known immune checkpoints including PD-1 or CTLA-4 that are successfully targeted
with blocking antibodies for cancer immunotherapy. The next generation active immune checkpoint control
immunotherapy which based on a Specific Total Immune Remodeler Platform demonstrate the ability to
activate and use the full potential of the patient’s own immune system to eradicate cancer and is able to induce
the killing of tumor target expressing cells by simultaneously activating all possible immunological pathways
(humoral and cellular), thus, succeed in controlling all the relevant immune checkpoints that prevent the
immune system from attacking and defeating cancer.
Biography
Jian Ni obtained his M.D. from Second Military Medical University and Ph.D. from University of Cambridge. Dr. Ni was a Post-doctoral
Fellow at the National Cancer Institute and University of California, Irvine. He is an American Society of Clinical pathologists board
certified Specialist in Immunology. Dr. Ni was a Senior Scientist of Human Genome Sciences, Inc., and has many years of experience
in biomedical research, immunology, oncology and protein chemistry, and industrial experience in functional genomics, therapeutic
protein and antibodies discovery and development. He has published more than 117 scientific articles in top scientific journals (IF
>600), Inventor of 251 issued US patents, 4 FDA approved antibody drugs and more than 10 antibody drugs in clinical trials were
based on these inventions.
13818096617@139.comJ Mol Cancer, Volume 2